California Proceeds With Manufacturing Its Own Generics
As Generic Drug Pricing Bill Gets Approval
With the legislature’s green light on California’s Generic Drug Pricing Bill, the state aims to manufacture generics while addressing shortages in the prescription drug market, expanding access to life-saving generic prescription drugs and improving patient health outcomes and overall public health.
You may also be interested in...
California’s recently approved Generic Drug Pricing Bill gives its Health and Human Services Agency the authority to enter contracts with drug manufacturers with the main aim of increasing competition, lowering prices and addressing shortages in the market for generic prescription drugs.
California’s 2020-2021 fiscal budget includes plans to work with manufacturers to establish the state’s own generics label. But industry is sceptical that the initiative will deliver the savings that the US state hopes for.
The FDA has revealed details of its recent warning letter to Shilpa, which cites the company’s failure to adequately investigate out-of-specification results and complaints as well as to follow written procedures for complaint handling.